Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13RÎ±2 CAR T Cell Program for Glioblastoma), and others.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
29/09/26	US$2.200	+1.38%	256,651
28/09/26	US$2.170	-4.82%	263,258
25/09/26	US$2.280	0.00%	264,894
24/09/26	US$2.280	-2.56%	203,678
23/09/26	US$2.340	-4.49%	331,816

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.200USD

Average target price

5.000USD

Spread / Average Target

+127.27%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq 21:00:00 29/09/2026 BST			5-day change	1st Jan Change
2.200 ^USD	+1.38%		-8.71%	-39.89%

08-13	Fortress Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-13	Fortress Biotech, Inc., Q2 2026 Earnings Call, Aug 12, 2026

Market Cap	73.37M 64.71M 61.21M 55.47M 104M 7.04B 105M 733M 282M 3.6B 275M 269M 11.55B	P/E 2026 *	0.86x	P/E 2027 *	-2.2x
Enterprise Value	73.37M 64.71M 61.21M 55.47M 104M 7.04B 105M 733M 282M 3.6B 275M 269M 11.55B	EV / Sales 2026 *	0.93x	EV / Sales 2027 *	0.65x
Free-Float	77.3%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq	FBIO	Delayed
CBOE	FBIO	Real-time

08-13	Fortress Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-13	Fortress Biotech, Inc., Q2 2026 Earnings Call, Aug 12, 2026
05-14	Fortress Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-21	Journey Medical Corporation secures contract with third major GPO for Emrosi	RE
03-31	Fortress Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	Fortress Biotech Unit Closes $205 Million PRV Sale	MT
02-23	Fortress Biotech Subsidiary Agrees to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million	MT
01-13	Fortress Biotech shares hit near two-week low, last down 6.6%	RE
01-13	Fortress Biotech seen surging after FDA approval
01-13	Fortress Biotech and Cyprium Therapeutics Announce U.S. Fda Approval of Zycubo	CI
01-13	Fortress Biotech, Cyprium Say FDA Approved Zycubo for Pediatric Patients of Menkes Disease; Shares Rise Pre-Bell	MT
01-13	US FDA approves Fortress Bio and Zydus' treatment for a rare pediatric disease	RE
01-13	Fortress Biotech and Cyprium Therapeutics announce U.S. FDA approval of Zycubo® (copper histidinate), the first and only approved treatment for Menkes disease in the United States	RE

Fortress Biotech, Inc. Share Price

Stocks

FBIO

US34960Q3074

Pharmaceuticals

Valuation: Fortress Biotech, Inc.

Chart: Fortress Biotech, Inc.

Latest news: Fortress Biotech, Inc.

Last Transcript: Fortress Biotech, Inc.

Analysts' recommendations: Fortress Biotech, Inc.

Press Releases: Fortress Biotech, Inc.

News in other languages: Fortress Biotech, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Fortress Biotech, Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

01/10/25	Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101	CI
01/10/25	Fortress Biotech Shares Drop After FDA Letter for CUTX-101 Manufacturing Facility	DJ
01/10/25	Fortress Biotech and Cyprium Therapeutics announce an update on the NDA for CUTX-101	RE
19/03/24	Alliance Global Partners Initiates Fortress Biotech at Buy Rating With $5 Price Target	MT
29/11/23	Roth MKM Lowers Price Target on Fortress Biotech to $15 From $30, Maintains Buy Rating	MT

09-08	Journey Medical Corporation to Participate in September 2026 Investor Conferences	AQ
09-08	Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
08-13	Fortress Biotech: Q2 Earnings Snapshot	AQ
08-13	Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights	AQ
08-12	Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights	AQ

01-13	Fortress Biotech attendu en forte hausse après une approbation de la FDA
29/09/21	MÄRKTE USA/Nur maue Erholung - Belastungsfaktoren bleiben
29/09/21	MÄRKTE USA/Moderate Erholung von Vortagesabsturz
30/09/20	Israël limite les manifestations dans le cadre de mesures sanitaires
30/09/20	France : l'inflation a ralenti à 0,1% sur un an en septembre

1 day	+1.38%
1 week	-8.71%
Current month	-19.56%
1 month	-20.58%
3 months	-20.29%
6 months	-20.29%
Current year	-39.89%

1 week	2.14	2.44
1 month	2.14	2.8
Current year	2.14	4.53
1 year	2.14	4.53
3 years	1.24	5.25
5 years	1.24	55.35
10 years	1.24	91.5

Manager	Title	Age	Since
Lindsay Rosenwald CEO	Chief Executive Officer	71	19/12/2013
Xiao Qin Lu DFI	Director of Finance/CFO	51	21/02/2012
David Jin DFI	Director of Finance/CFO	36	15/08/2022

Director	Title	Age	Since
Jimmie Harvey BRD	Director/Board Member	74	30/11/2008
Lindsay Rosenwald CHM	Chairman	71	19/12/2013
J. Jay Lobell BRD	Director/Board Member	63	31/05/2006

Date	Insider	Type	Main position	Quantity	% Market Cap.
01/04/26	David Jin	Free	Chief Financial Officer	2,967	0.0096%
18/03/26	Lindsay Rosenwald	Free	Chief Executive Officer	475,424	1.5318%
18/03/26	Michael Weiss	Free	Director	475,424	1.5318%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FORTRESS BIOTECH, INC.	+1.38%	-8.71%	-43.73%	-51.11%	72.37M
MODERNA, INC.	+3.13%	+17.65%	+730.79%	+102.91%	78.76B
REGENERON PHARMACEUTICALS, INC.	-0.23%	-5.97%	+33.09%	-10.07%	75.12B
CSL LIMITED	+0.21%	+2.24%	-6.14%	-27.67%	61.14B
UCB	-2.68%	-2.50%	+5.03%	+165.47%	46.07B
SAMSUNG BIOLOGICS CO.,LTD.	-1.07%	-1.21%	-9.92%	+32.27%	47.57B
BIOGEN INC.	-0.71%	+3.65%	+65.30%	-11.93%	33.79B
INCYTE CORPORATION	-1.30%	-1.16%	+48.97%	+110.20%	25.3B
INNOVENT BIOLOGICS, INC.	-0.26%	-6.35%	+2.84%	+140.35%	21.34B
SWEDISH ORPHAN BIOVITRUM AB	-0.64%	-1.58%	+60.16%	+95.78%	15.36B
Average	-0.22%	-1.17%	+88.64%	+54.62%	40.45B
Weighted average by Cap.	-0.01%	+0.45%	+157.86%	+53.55%

	2026 *	2027 *
Net sales	78.79M 69.49M 65.74M 59.57M 112M 7.56B 113M 787M 303M 3.86B 296M 289M 12.4B	113M 99.88M 94.48M 85.62M 161M 10.87B 162M 1.13B 436M 5.55B 425M 416M 17.83B
Net income	88.25M 77.83M 73.62M 66.72M 125M 8.47B 126M 882M 340M 4.33B 331M 324M 13.89B	-37.81M -33.35M -31.55M -28.59M -53.65M -3.63B -54.13M -378M -146M -1.85B -142M -139M -5.95B
Net Debt	-	-